Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 25, 2021 - Issue 5
Submit an article Journal homepage
1,914
Views
35
CrossRef citations to date
0
Altmetric
Editorial

Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology

Stergios Boussiosa King’s College London, Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, London, UK;b Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK;c AELIA Organization, Thessaloniki, GreeceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2512-6131
ORCID Icon,
Elie Rassyd Department of Cancer Medicine, Gustave Roussy Institut, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0002-7906-0991
ORCID Icon,
Sidrah Shahb Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK
,
Evangelia Ioannidoue Department of Paediatrics and Child Health, West Suffolk Hospital NHS Foundation Trust, Hardwick Lane, Bury St Edmunds, Suffolk, UK
,
Matin Sheriffb Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK
&
Nicholas Pavlidisf Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece
Pages 329-333 | Received 31 Mar 2021, Accepted 30 Jun 2021, Published online: 08 Jul 2021

References

  • Saxby H, Mikropoulos C, Boussios S. An update on the prognostic and predictive serum biomarkers in metastatic prostate cancer. Diagnostics (Basel). 2020;10(8):549.
  • Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228.
  • Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014;66(3):489–499.
  • Abeshouse A, Ahn J, Akbani R, Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–1025.
  • Hussain M, Mateo J, Fizazi K, et al. PROfound trial investigators. survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345–2357.
  • Castro E, Romero-Laorden N, Del Pozo A, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-Resistant prostate cancer. J Clin Oncol. 2019;37(6):490–503.
  • Boussios S, Karihtala P, Moschetta M, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs. 2020;38(1):181–193.
  • Boussios S, Abson C, Moschetta M, et al. Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond. Drugs R D. 2020;20(2):55–73.
  • Mateo J, Carreira S, Sandhu S, et al. DNA-Repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–1708.
  • Mateo J, Porta N, Bianchini D, et al., Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1): 162–174.
  • Abida W, Campbell D, Patnaik A, et al., Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis From the phase II TRITON2 study. Clin Cancer Res. 2020;26(11): 2487–2496.
  • Smith MR, Sandhu SK, Kelly WK, et al. Pre-specified interim analysis of GALAHAD: a phase 2 study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Ann Oncol. 2019;30:v851–v934.
  • Pomerantz MM, Spisák S, Jia L, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017;123(18):3532–3539.
  • Antonarakis ES, Piulats JM, Gross-Goupil M, et al., Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38(5): 395–405.
  • Boussios S, Mikropoulos C, Samartzis E, et al. Wise management of ovarian cancer: on the cutting edge. J Pers Med. 2020;10(2):41.
  • Giri VN, Knudsen KE, Kelly WK, et al. Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019. J Clin Oncol. 2020;38(24):2798–2811.
  • Bryce AH, Sartor O, De Bono J. DNA repair and prostate cancer: a field ripe for harvest. Eur Urol. 2020;78(4):486–488.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.